期刊文献+

基于分光光度法测定血液中非那西丁与扑热息痛含量的肝脏储备功能评估 被引量:1

Assessment of liver reserve function based on determination of phenacetin and paracetamol by spectrophotometry
下载PDF
导出
摘要 目的建立基于分光光度法测定非那西丁与扑热息痛含量的肝脏储备功能评估方法。方法筛选分光光度测定的显色体系,确定最大吸收波长,分析不同因素对显色体系的影响,优化非那西丁与扑热息痛水解的最佳条件,最后对技术体系进行应用性验证。结果建立了利用分光光度测定样品中非那西丁和扑热息痛含量的技术体系,即样品加入3 mol/L盐酸水解30 min,加入0.02%1,2-萘醌-4-磺酸钠、1%十六烷基三甲基溴化铵及2%Na OH(或3%Na2CO3)(比例为1∶6∶1∶2或3),分别于500 nm和570 nm下测定吸光值,计算各自浓度。该技术测定血浆样品中非那西丁与扑热息痛时的分辨率和重复性与高效液相色谱法相当。结论利用分光光度技术测定血液中非那西丁与扑热息痛含量,二者比值具有评估肝脏储备功能价值。 Objective To establish a liver reserve function assessment method based on detection of phenacetin and paracetamol by spectrophotometry. Methods To screen the spectrophotometric color system,determine the maximum absorption wavelength,analyze the influence of color system in different factors,optimize optimal conditions that phenacetin and paracetamol hydrolyze,and then verify the application of this technology about the established system. Results The technology system detected phenacetin and paracetamol of blood samples using spectrophotometry was established,in which3 mol / L hydrochloric acid was added to samples to hydrolyze for 30 min,then added 0. 02% 1,2-naphthoquinone-4-sulfonate,1% sixteen alkyl bromide and 2% sodium hydroxide( or 3% sodium carbonate)( ratio of 1∶ 6∶ 1∶ 2 or 3),and then the absorbance was measured under 500 nm and 570 nm to calculate each concentration. Resolution and repeatability of technology used for determining phenacetin and paracetamol of plasma samples were comparable with HPLC. Conclusion Ratio of phenacetin and paracetamol under established spectrophotometric system could assess liver reserve function.
出处 《山东医药》 CAS 北大核心 2015年第4期14-17,共4页 Shandong Medical Journal
基金 山东省科技攻关项目(2009GG10002005) 山东省医药卫生科研项目(2007HW116)
关键词 肝脏储备功能 分光光度技术 非那西丁 扑热息痛 liver reserve function spectrophotometry phenacetin paracetamol
  • 相关文献

参考文献8

二级参考文献110

  • 1朱大岭,贺锡雯.CYP1A1基因型与吸烟及肺癌的关系[J].国外医学(卫生学分册),1996,23(2):96-98. 被引量:6
  • 2许振华,周宏灏.细胞色素氧化酶P4501A2与药物代谢[J].中国临床药理学杂志,1996,12(2):115-121. 被引量:22
  • 3任彭,刘兆平.细胞色素P450研究概况及其应用[J].食品与药品,2006,8(10A):8-13. 被引量:17
  • 4孟宪镛.肝功能试验.见:梁扩寰,李绍白主编.肝脏病学.第2版.北京:人民卫生出版社,2003.200-260.
  • 5[1]Wrighton SA, vardonbradon M, Ring BJ. The human drug metabolizing cytochromes P450. J pharmacokinet Biopharn, 1996,26:461
  • 6[2]Chen S,Chou WH,Blouin RA,et al .The cytochroem P4502D6(CYP2D6)enzyme polymorphism:screening costs and influence on clinical outcomes in psychiatry. Clin Pharmacol Ther, 1996,60: 522
  • 7[3]Cai WM,chen B,liu YX, et al. Dextromethorphan metabclic phenotyping in a native Chinese population. Acta Pharmacologica Sinic, 1997,18(5):441 ~444
  • 8[4]Kulow W. The genetic defect of mepheytoin hydroxylation Xenobiotica.1986,16:379 ~ 389
  • 9[10]Ward SA , Helshy NA, Skjelbo E. The activation of the biguanid antimalarial proguanil cosegregates with the mephenytion oxidation polymorphism a panel study. Br J clin pharmacol, 1991,31:689
  • 10[11]Koop DR. Oxidative and reductive metabolism by cytochrone P4502E1.FASEB J, 1992,6:724

共引文献66

同被引文献7

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部